Sickle cell disease effects the African American population. Its acute manifestations include pain crisis involving bones, the priapism, acute chest syndrome, strokes, acute renal or hepatic disease. Most commonly, patients are hospitalized with bone pain crisis requiring intervenous pain medications for several days. These painful episodes interfere with the normal life and function of the patients. The study is designed to assessed a safety and tolerability of repeated exposure to FLOCOR in patients with vaso-occlusive pain crisis of sickle cell disease. FLOCOR is a trade name for purified poloxamer 188. This polymer coats the red blood cells negating their surface electrical charge such that red cells will not adhere to each other or to the vascular endothelium. It also decreases the blood viscosity. FLOCOR will likely help in reducing the duration and the severity of pain. Its clinical effectiveness in sickle cell pain crisis is being evaluated in a randomized placebo controlled trial. This trial has enrolled 134 patients. The total number of patients to be enrolled is 224. The current proposed study will be an open label safety extension study of the above study. Side effects in the 134 patients enrolled to date in the placebo controlled trial are minimal and may include hyperbilirubinemia and fever. The side effects, if any, are reversible on withdrawal of the drug. The proposed safety study will enroll 30 patients at six centers. The patients will have either participated in the Phase III Multicenter study that is ongoing or they would have been ineligible for that study. The dose of FLOCOR is 100 mg/kg given IV over one hour, followed by 30 mg/kg per hr for 47 hours intravenously. The patients may receive a maximum of six courses of FLOCOR within a period of one year from enrollment on the study. Patients ages 10 and less than 65 years of ages with confirmed sickle cell disease will be enrolled. At the time of each treatment, patients will be experiencing acute pain typical of sickle cell disease crisis requiring hospital admission. The patients must meet all the eligibility criteria prior to each treatment on this protocol. The safety, tolerability, and sickle cell disease related events will be monitored.

National Institute of Health (NIH)
National Center for Research Resources (NCRR)
General Clinical Research Centers Program (M01)
Project #
Application #
Study Section
General Clinical Research Centers Committee (CLR)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code
Chappell, Cynthia L; Darkoh, Charles; Shimmin, Lawrence et al. (2016) Fecal Indole as a Biomarker of Susceptibility to Cryptosporidium Infection. Infect Immun 84:2299-306
Liao, George P; Harting, Matthew T; Hetz, Robert A et al. (2015) Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med 16:245-55
Arroyo-Ávila, Mariangelí; Santiago-Casas, Yesenia; McGwin Jr, Gerald et al. (2015) Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. Clin Rheumatol 34:1217-23
Chappell, Cynthia L; Okhuysen, Pablo C; Langer-Curry, Rebecca C et al. (2015) Cryptosporidium muris: infectivity and illness in healthy adult volunteers. Am J Trop Med Hyg 92:50-5
Reveille, John D (2014) An update on the contribution of the MHC to AS susceptibility. Clin Rheumatol 33:749-57
Bethi, Siddharth; Dasgupta, Abhijit; Weisman, Michael H et al. (2013) Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative? Arthritis Care Res (Hoboken) 65:607-14
Ward, Michael M; Learch, Thomas J; Gensler, Lianne S et al. (2013) Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease. Arthritis Care Res (Hoboken) 65:257-65
Benjamin-Garner, Ruby; Stotts, Angela (2013) Impact of smoking exposure change on infant birth weight among a cohort of women in a prenatal smoking cessation study. Nicotine Tob Res 15:685-92
Ornstein, Tisha J; Max, Jeffrey E; Schachar, Russell et al. (2013) Response inhibition in children with and without ADHD after traumatic brain injury. J Neuropsychol 7:1-11
Murthy, Vijaya; Willis, Rohan; Romay-Penabad, Zurina et al. (2013) Value of isolated IgA anti-?2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 65:3186-93

Showing the most recent 10 out of 396 publications